ArticleJournal of cellular physiology2019
Interleukin-37 inhibits osteoclastogenesis and alleviates inflammatory bone destruction.
Article in Journal of cellular physiology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 28 citations in OpenAlex.
- GDF15 Contributes to the Regulation of the Mechanosensitive Responses of PdL Fibroblasts through the Modulation of IL-37.Dentistry journal · 2024Article
- Caffeine regulates both osteoclast and osteoblast differentiation via the AKT, NF-κB, and MAPK pathways.Frontiers in pharmacology · 2024Article
- Fibulin2: a negative regulator of BMSC osteogenic differentiation in infected bone fracture healing.Experimental & molecular medicine · 2023Article
- The selected genes NR6A1, RSAD2-CMPK2, and COL3A1 contribute to body size variation in Meishan pigs through different patterns.Journal of animal science · 2023Article
- Role of Interleukin-1 family in bone metastasis of prostate cancer.Frontiers in oncology · 2022Review
- Elevated levels of interleukin-35 and interleukin-37 in adult patients with obstructive sleep apnea.Journal of clinical laboratory analysis · 2021Article
- IL-1 Family Antagonists in Mouse and Human Skin Inflammation.Frontiers in immunology · 2021Review
- Article
- Dendritic cells-derived interferon-λ1 ameliorated inflammatory bone destruction through inhibiting osteoclastogenesis.Cell death & disease · 2020Article
- IL-37b alleviates inflammation in the temporomandibular joint cartilage via IL-1R8 pathway.Cell proliferation · 2019Article
- IL-37- and IL-35/IL-37-Producing Plasma Cells in Chronic Periodontitis.Journal of dental research · 2019Article
- Diallyl disulfide alleviates inflammatory osteolysis by suppressing osteoclastogenesisFASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2019Article
- Interleukin-37 inhibits osteoclastogenesis and alleviates inflammatory bone destruction.Journal of cellular physiology · 2019Article
- IL-36, IL-37, and IL-38 Cytokines in Skin and Joint Inflammation: A Comprehensive Review of Their Therapeutic Potential.International journal of molecular sciences · 2019Review
- Interleukin-27 prevents LPS-induced inflammatory osteolysis by inhibiting osteoclast formation and function.American journal of translational research · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Excessive osteoclast formation is one of the important pathological features of inflammatory bone destruction. Interleukin-37 (IL-37) is an anti-inflammatory agent that is present throughout the body, but it displays low physiological retention. In our study, high levels of the IL-37 protein were detected in clinical specimens from patients with bone infections. However, the impact of IL-37 on osteoclast formation remains unclear. Next, IL-37 alleviated the inflammatory bone destruction in the mouse in vivo. We used receptor activator of nuclear factor-κB ligand and lipopolysaccharide to trigger osteoclastogenesis under physiological and pathological conditions to observe the role of IL-37 in this process and explore the potential mechanism of this phenomenon. In both induction models, IL-37 exerted inhibitory effects on osteoclast differentiation and bone resorption. Furthermore, IL-37 decreased the phosphorylation of inhibitor of κBα and p65 and the expression of nuclear factor of activated T cells c1, while the dimerization inhibitor of myeloid differentiation factor 88 reversed the effects. These data provide evidence that IL-37 modulates osteoclastogenesis and a theoretical basis for the clinical application of IL-37 as a treatment for bone loss-related diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.